ProtierBiotech Raises $2.45M for Cancer Drug Pipeline

South Korean biotechnology firm ProtierBiotech has successfully closed a Pre-Series A funding round, securing approximately $2.45 million (KRW 3.5 billion). This capital infusion is earmarked to accelerate the development of its innovative molecular glue-based cancer therapies, a rapidly advancing area within oncology drug discovery.

The funding round saw robust participation from a consortium of notable investors, including Hana Ventures, IBK Venture Investment, T Investment, Mirae Holdings, and Korea Investment Accelerator. This collective backing underscores confidence in ProtierBiotech's proprietary platform, which aims to overcome the limitations of existing cancer treatments by precisely targeting disease mechanisms.

ProtierBiotech is strategically pursuing a dual-pronged approach to drug development. The company is advancing both molecular glue-enhanced antibody-drug conjugates (ADCs) and standalone molecular glue therapeutics. This integrated strategy is designed to create a competitive edge in the highly dynamic field of cancer therapeutics, where novel mechanisms of action are crucial for therapeutic success.

The company's lead programs are initially focused on multiple myeloma, a challenging hematological malignancy. Beyond this primary indication, ProtierBiotech intends to leverage the new funding to expand its pipeline, with plans to investigate potential treatments for ovarian cancer. This expansion reflects a broader ambition to address a wider spectrum of oncological needs.

External validation for ProtierBiotech's technology has been significant. The company was previously selected for the Korea Drug Development Fund’s (KDDF) “New Drug R&D Ecosystem Building Research” program and subsequently named to the Ministry of SMEs and Startups’ Scale-Up TIPS program. These recognitions highlight the scientific merit and commercial potential of its molecular glue platform.

“This financing represents a pivotal moment, validating our molecular glue technology and our capacity for drug development in the market,” stated Hyuntae Kim, CEO of ProtierBiotech. “Our immediate priority is advancing our multiple myeloma candidate, while concurrently exploring strategic license-out opportunities with global pharmaceutical leaders. We are positioning ProtierBiotech as a significant innovator on the international biotech stage.” The company plans to utilize the funds to progress its programs into preclinical stages and bolster its overall drug development infrastructure.